NuggMD, the leading telehealth platform for cannabis, today announced that it has launched in the United Kingdom and has integrated with Stripe to reduce friction at the point of sale for prescription-only medical cannabis patients in the United Kingdom.

This implementation is a core part of the company's approach to expanding into international markets. Stripe builds programmable financial services and simplifies online purchases to improve the customer experience.

“We are honored to be launching in the UK and working with Stripe has been a dream. The boundaries that they are pushing in the payments landscape are unmatched,” said NuggMD CEO Charlie Russell.

Seventy-nine percent of cannabis consumers expect the dispensaries they shop at to accept debit card payments, according to a poll by The Cannabis Consumer Poll, NuggMD's in-house pollster, from last June. This shows the value of digital payment options in the cannabis sector.

Russell continued: “Consumers expect the ability to pay for cannabis as easily as they can pay for any other consumer product or service. Stripe’s ability to complete payments faster, more securely, and at a lower cost than traditional methods brings speed, confidence, and savings to the UK’s roughly 75,000 active patients and nearly 700,000 annual prescriptions processed online.”

NuggMD is the leading cannabis telehealth platform, connecting patients with licensed medical cannabis practitioners in most U.S. states, the United Kingdom, and Germany.

The company has facilitated more than 2 million medical cannabis evaluations since its founding in 2015. It also operates an in-house research and polling unit, The Cannabis Consumer Poll, which uses a representative sample of cannabis consumers who shop in the $47b state-legal, regulated cannabis markets.

This contant was orignally distributed by Newsworthy.ai. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NuggMD Integrates Stripe to Process Payments for UK Medical Cannabis Patients.